Phase I Study of Alternate‐Day Administration of S‐1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer

LESSONS LEARNED: The recommended S‐1 dose was 40 mg/m(2), twice daily on Monday, Wednesday, Friday, and Sunday, with oral leucovorin and bevacizumab. Compared with daily administration, the alternate‐day administration of S‐1 with oral leucovorin may reduce mucositis with promising antitumor activit...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Masuishi, Toshiki, Taniguchi, Hiroya, Komori, Azusa, Mitani, Seiichiro, Narita, Yukiya, Kadowaki, Shigenori, Ura, Takashi, Ando, Masashi, Muro, Kei
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2020
Onderwerpen:
Clinical Trial Results
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648368/
https://ncbi.nlm.nih.gov/pubmed/32490554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0463
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items